Here’s a back-to-school pop quiz for parents: How much do you think your child’s school grades or emotions are tied to whether you’re sitting down to dinner together? The answer: More than you might think.
All 18 rhesus monkeys infected with the virus survived after getting the experimental medication, researchers report
Having a dinner party? Whether it's a special occasion or a casual get-together, you can serve delicious dishes that everyone will enjoy.
Chef Bryan Caswell, of Houston's The Reef restaurant, dishes about a seafood-oriented Thanksgiving dinner.
About 500 new infections reported across West Africa, including first case in Senegal
MADRID (AP) — The parents of a 5-year-old British boy with a severe brain tumor they took abroad against doctors' advice were at a Madrid courthouse awaiting the start of proceedings Monday on whether to extradite them to the U.K.
Medical authorities in the Swedish capital said on Monday tests on a man brought into hospital over the weekend and suspected of potentially carrying Ebola showed no signs the deadly disease. The Swedish man, whose name was not disclosed, had recently traveled to a "risk area" for the virus and had been taken to the Karolinska University Hospital in Stockholm suffering from a fever, sparking suspicions of Ebola. Stockholm county council said in a statement the man would continue to be treated at the hospital to ascertain the cause of his symptoms. More than 1,500 people have died in an Ebola outbreak in West Africa since March.
By Ben Hirschler BARCELONA (Reuters) - Sales forecasts for Novartis's new heart failure drug are being ramped up by analysts after strikingly good clinical trial results for a medicine doctors expect to transform treatment of the deadly disease. David Epstein, Novartis' head of pharmaceuticals, said the launch of the drug next year promised to be the company's most exciting ever and profit margins on the medicine would be good. The results of a keenly-awaited clinical trial on LCZ696 were released at the annual meeting of the European Society of Cardiology on Saturday and published in the New England Journal of Medicine with a glowing editorial. Investigators working on the study and the company itself believe it has potential to replace drugs that have been central to treating heart failure for a quarter of century, opening up a multi-billion dollar sales opportunity.
The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities. The revelations, which marked the latest in a string of scandals at the company's Japanese subsidiary, come after local authorities slapped the firm on the wrist, saying it had to clean up its operations. On Friday, Novartis issued a statement saying it had failed to report to regulators at least 2,579 cases where patients had suffered serious potential side effects from its drugs. Japan's Jiji Press news agency said they included some fatal cases, without specifying a figure.